Skip to main content

Table 3 PROs of HCV patients receiving DAAs therapy prior, during and at the end of therapy

From: Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt

Variables/Time

  

Friedman test

Wilcoxon test

N

Mean + SD

Chi-Square

P-value

T

Z

P value (r)

HRQoL

 

 T0

36

31.02 ± 15.30

8.35

.01

T0 - T1 = 436

-2.37

.01 (-.30)

 T1

36

39.63 ± 21.11

 T2

36

34.50 ± 19.96

T1 –T2 = 178.50

-2.04

.04(-.26)

Symptom experience

 Symptom severity

  T0

36

23.19 ± 10.21

5.41

.06

T0 - T1 = 458

-1.97

.04(-.25)

  T1

36

27.36 ± 13.07

  T2

36

24.25 ± 12.75

 Symptom hindrance

  T0

36

7.83 ± 6.40

9.89

.007

T0 - T1 = 358

-2.58

.01(-.33)

  T1

36

12.27 ± 9.00

  T2

36

10.25 ± 7.89

Mental Health

 Depression

  T0

36

8.91 ± 7.25

8.79

.01

T0 - T1 = 385

-2.28

.02(-.29)

  T1

36

10.77 ± 7.18

  T2

36

8.97 ± 6.57

 Anxiety

  T0

36

7.33 ± 5.80

6.82

.03

T0 - T1 = 379

-2.57

.01(-.33)

  T1

36

8.88 ± 5.87

  T2

36

6.86 ± 6.05

T1 - T2 = 80

-2.63

.009(-.34)

 Stress

  T0

36

10.94 ± 7.35

4.86

.08

T1 - T2 = 103.50

-2.47

.01(-.32)

  T1

36

12.05 ± 6.83

  T2

36

9.75 ± 6.80

 MSPSS

  T0

36

2.41 ± .47

11.35

.003

T0 - T1 = 212

-2.27

.02(-.29)

  T1

36

2.51 ± .37

  T2

36

2.41 ± .39

T1 - T2 = 146

-2.77

.006(-.36)

  1. HRQoL Health-related quality of life time 0, T0 time 0, T1 time 1, T2 time 2
  2. P value significant at two tailed
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us